10/13/2026
More promising research on the potential of ketamine.
New findings presented at the 2026 American Psychiatric Association Annual Meeting looked at IV ketamine for people with moderate to severe obsessive-compulsive disorder (OCD).
In the Stanford study, participants who received a single ketamine infusion experienced a significant and rapid reduction in OCD symptoms, with about half meeting the study’s response criteria at one and two weeks.
While ketamine is not FDA-approved for the treatment of OCD and more research is needed, studies like this are encouraging for people who continue to struggle despite traditional treatment options.
At Atlanta Ketamine Center, we are always interested in following the evolving research surrounding ketamine and its potential applications in mental health care.
Read more about the study below.
Stanford researchers presented unpublished APA 2026 data showing a single ketamine infusion dramatically reduces OCD symptoms — with effects lasting 3 weeks.